^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FP-1039

    i
    Associations
    News

    Trials

    Company:
    Amgen
    Drug class:
    FGFR1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study of FP-1039 in Subjects With Endometrial Cancers (NCT01244438)
    Phase 2
    Five Prime Therapeutics, Inc.
    Withdrawn
    Last update posted :
    12/13/2021
    Initiation :
    01/01/2011
    Primary completion :
    06/01/2012
    Completion :
    12/01/2012
    FGFR2 • FGFR
    |
    FGFR2 mutation • FGFR mutation • FGFR2 S252W
    |
    FP-1039
    Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling (NCT01868022)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    08/19/2019
    Initiation :
    10/09/2013
    Primary completion :
    10/24/2017
    Completion :
    10/24/2017
    FGF2
    |
    FGFR1 amplification • FGFR1 expression
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • FP-1039